# Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Study · id `cardio:ct-nct04083339` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04083339](<https://clinicaltrials.gov/study/NCT04083339>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04083339

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 675 participants.

## Technical summary

Registry record NCT04083339. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-20 (actual); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 675 participants (planned count; ClinicalTrials.gov record NCT04083339, source copy `cardio:ctgov-nct04083339-2022-12-08`, retrieved 2026-10-26)
- Started: 2019-09-20 (actual) (ClinicalTrials.gov record NCT04083339, source copy `cardio:ctgov-nct04083339-2022-12-08`, retrieved 2026-10-26)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT04083339, source copy `cardio:ctgov-nct04083339-2022-12-08`, retrieved 2026-10-26)
- Completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT04083339, source copy `cardio:ctgov-nct04083339-2022-12-08`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Czechia; France; Germany; Hong Kong SAR China; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT04083339, source copy `cardio:ctgov-nct04083339-2022-12-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04083339-2022-12-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
- Condition: Diabetic Cardiomyopathies
- Intervention (Drug): AT-001
- Intervention (Drug): Placebo
- Lead sponsor: Applied Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy (`cardio:pubmed-38597864`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy (`cardio:pubmed-39095808`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial (`cardio:pubmed-39806375`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis (`cardio:pubmed-39882614`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study (`cardio:pubmed-40338768`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial (`cardio:pubmed-42538062`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fafc79562770244b00d282f811ce896ed60ce61c3c2c842f6b088675d64592f4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
